A Smart + Strong Site
Subscribe to:
Newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

January 4, 2011

J&J Invests in New Noninvasive Cancer Test

Johnson & Johnson (J&J) has announced that it is investing $30 million in a new test that could detect—and help doctors treat—a variety of cancers from a simple blood draw, according to reporting by Yahoo Canada News. While experts concede that such a test is still years away, some are predicting that it could revolutionize cancer detection and treatment.

Several years ago, doctors at Massachusetts General Hospital created an assay designed to count the number of cancerous cells that were spreading from invasive and aggressive tumors. The test, called CellSearch, is now made and sold by a J&J subsidiary called Veridex. While it has helped somewhat in assessing the behavior and spread of serious metastatic tumors—such as colorectal cancer—it is not particularly precise.

The new test, to which J&J is now pouring new money, aims to be far more accurate and provide much richer detail.

In addition to counting cells, the experimental assay can capture cancer cells and allow doctors to understand exactly how the cells are behaving and developing. This new level of precision could help guide in almost real time how to manage cancer treatment without invasive biopsies or cumbersome and expensive computed tomography (CT) scans.

“This is like a liquid biopsy,” Daniel Haber, MD, chief of Massachusetts General Hospital’s cancer center and one of the test’s inventors, told Yahoo.

“If you could find out quickly, ‘This drug is working, stay on it,’ or ‘This drug is not working, try something else,’ that would be huge,” Haber continued.

Experts caution that similar tests have not panned out in the past. One, GeneSearch, was originally lauded for its promise in helping detect the spread of breast cancer cells to lymph nodes. It was later scrapped, however, because it was very expensive and too often gave false positive results.

Experts say that it could take years to test the new assay against the various cancers to which it would be applied. It is also not clear how much it will cost, nor what the machine that will run the assay will look like or how it will function.

Despite this uncertainty, Greg Vrettos, a 63-year-old lung cancer survivor from Durham, New Hampshire, has already benefited from an early prototype of the test. A previous biopsy had collapsed his lungs four years ago, which illustrates why biopsies can be both dangerous and unpleasant. The new assay, however, along with CT scans, has given Vrettos’s doctors a noninvasive tool to help choose the best treatment and keep him on it—and alive—for several years now.

“I think [the new assay is] going to be revolutionary,” Vrettos said.

Search: Johnson & Johnson, J&J, Veridex, cancer, blood test, Daniel Haber, Greg Vrettos, assay, microchip


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)


[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    guycmh328
    Columbus
    Ohio


    koffeeboss
    Tucson
    Arizona


    usuallyhappy
    Palm Springs
    California


    HOTROD2010
    houston
    Texas
Click here to join POZ Personals!
Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014


21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.